ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.27
-1.00 (-4.91%)
Mar 31, 2025, 1:15 PM EDT - Market open
ADMA Biologics Revenue
In the year 2024, ADMA Biologics had annual revenue of $426.45M with 65.15% growth. ADMA Biologics had revenue of $117.55M in the quarter ending December 31, 2024, with 59.06% growth.
Revenue (ttm)
$426.45M
Revenue Growth
+65.15%
P/S Ratio
11.07
Revenue / Employee
$622,561
Employees
685
Market Cap
4.58B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 426.45M | 168.24M | 65.15% |
Dec 31, 2023 | 258.22M | 104.13M | 67.59% |
Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ADMA News
- 9 days ago - ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential - Seeking Alpha
- 26 days ago - BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls - GlobeNewsWire
- 27 days ago - ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 27 days ago - ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - ADMA Biologics to Participate in the Raymond James Institutional Investor Conference - GlobeNewsWire
- 4 weeks ago - ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - GlobeNewsWire
- 7 weeks ago - ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add - Seeking Alpha
- 3 months ago - ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility - GlobeNewsWire